Ligand Pharmaceuticals Inc. (LGND)

104.00
0.69 0.66
NASDAQ : Health Technology
Prev Close 104.69
Open 104.70
Day Low/High 103.09 / 107.67
52 Wk Low/High 84.45 / 278.62
Volume 977.87K
Avg Volume 421.10K
Exchange NASDAQ
Shares Outstanding 19.01M
Market Cap 1.89B
EPS 6.80
P/E Ratio 2.97
Div & Yield N.A. (N.A)
Ligand Partner Seelos Therapeutics Becomes A Public Company

Ligand Partner Seelos Therapeutics Becomes A Public Company

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc.

Nvidia, Microsoft, Kimberly-Clark: 'Mad Money' Lightning Round

Nvidia, Microsoft, Kimberly-Clark: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Nvidia, Microsoft, Kimberly-Clark, Ligand Pharmaceutical, Edison International, Consolidated Edison, ArcBest and more.

Snapping the Win Streak: Cramer's 'Mad Money' Recap (Tuesday 1/22/19)

Snapping the Win Streak: Cramer's 'Mad Money' Recap (Tuesday 1/22/19)

From earnings to oil and fund managers, Jim Cramer breaks down this market action.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Ligand Pharmaceuticals Incorporated

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Ligand Pharmaceuticals Incorporated

The law firm of Kirby McInerney LLP is investigating potential claims against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND).

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Left's firm Citron Research gives the $100+ stock a $35 price target.

Ligand To Report Fourth Quarter And Full Year 2018 Results On February 7th

Ligand To Report Fourth Quarter And Full Year 2018 Results On February 7th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2018 financial results on February 7, 2019.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EBR.B Downgrades: AGTC, AL, CAMP, GOLD, LGND, SNV Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Notable Friday Option Activity: LGND, CPE, AAOI

Notable Friday Option Activity: LGND, CPE, AAOI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ligand Pharmaceuticals Inc , where a total volume of 4,974 contracts has been traded thus far today, a contract volume which is representative of approximately 497,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 96.1% of LGND's average daily trading volume over the past month, of 517,610 shares.

Ligand Introduces 2019 Financial Outlook And Raises 2018 Financial Guidance

Ligand Introduces 2019 Financial Outlook And Raises 2018 Financial Guidance

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) introduces its financial outlook for 2019.

Ligand Acquires Milestone And Royalty Rights To PTX-022 From Palvella Therapeutics

Ligand Acquires Milestone And Royalty Rights To PTX-022 From Palvella Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to PTX-022 from Palvella Therapeutics.

Vernalis Research, A Ligand Company, Achieves Success Milestone In Collaboration With Asahi Kasei Pharma

Vernalis Research, A Ligand Company, Achieves Success Milestone In Collaboration With Asahi Kasei Pharma

Vernalis Research, a Ligand Company, announced the achievement of a £1 million success milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP).

Ligand Announces OmniAb® Partnership With IMetabolic Biopharma Corporation

Ligand Announces OmniAb® Partnership With IMetabolic Biopharma Corporation

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company located in Tempe, AZ.

Vernalis Research, A Ligand Company, Achieves Success Milestones In Collaboration With Daiichi Sankyo

Vernalis Research, A Ligand Company, Achieves Success Milestones In Collaboration With Daiichi Sankyo

Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began in December of 2017.

Ligand Reports Third Quarter 2018 Financial Results

Ligand Reports Third Quarter 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates.

Ligand To Participate In Stephens NY Investment Conference

Ligand To Participate In Stephens NY Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in Stephens NY Investment Conference in New York City.

Notable Thursday Option Activity: LGND, ARRY, SN

Notable Thursday Option Activity: LGND, ARRY, SN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ligand Pharmaceuticals Inc , where a total volume of 3,454 contracts has been traded thus far today, a contract volume which is representative of approximately 345,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 56.1% of LGND's average daily trading volume over the past month, of 616,225 shares.

Ligand To Report Third Quarter 2018 Results On November 8th

Ligand To Report Third Quarter 2018 Results On November 8th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2018 financial results on November 8, 2018.

Ligand Announces The Close Of Its Acquisition Of Vernalis

Ligand Announces The Close Of Its Acquisition Of Vernalis

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its acquisition of Vernalis plc has successfully closed and Vernalis will now operate as a subsidiary of Ligand.

Ligand To Participate In H.C. Wainwright 20th Annual Global Investment Conference

Ligand To Participate In H.C. Wainwright 20th Annual Global Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in H.

Ligand Makes Offer To Acquire Vernalis, A Leader In Structure-Based Drug Discovery, For Approximately $43 Million In Cash

Ligand Makes Offer To Acquire Vernalis, A Leader In Structure-Based Drug Discovery, For Approximately $43 Million In Cash

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Vernalis plc (LSE: VER) announce that Ligand has declared its firm intention to acquire the entire issued and to be issued shares of Vernalis through a UK scheme of arrangement conditional on approval...

Ligand Reports Second Quarter 2018 Financial Results

Ligand Reports Second Quarter 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2018, and provided an operating forecast and program updates.

Ligand Pharmaceuticals Larger Than S&P 500 Component Discovery

Ligand Pharmaceuticals Larger Than S&P 500 Component Discovery

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ligand Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Discovery Inc , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Ligand To Report Second Quarter 2018 Results On August 6th

Ligand To Report Second Quarter 2018 Results On August 6th

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report second quarter 2018 financial results on August 6, 2018.

Ligand Receives $47 Million From WuXi Biologics For Expansion Of Worldwide OmniAb® Platform License Agreement

Ligand Receives $47 Million From WuXi Biologics For Expansion Of Worldwide OmniAb® Platform License Agreement

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has received $47 million as a result of signing an amendment relating to its OmniAb platform agreement with WuXi Biologics ("WuXi Bio", SEHK: 2269.

Ligand Prices Offering Of $650 Million Of Convertible Senior Notes

Ligand Prices Offering Of $650 Million Of Convertible Senior Notes

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today the pricing of $650 million aggregate principal amount of 0.

Ligand Announces Proposed Offering Of $650 Million Of Convertible Senior Notes

Ligand Announces Proposed Offering Of $650 Million Of Convertible Senior Notes

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it intends to offer, subject to market conditions and other factors, $650 million aggregate principal amount of convertible senior notes due 2023 in a private offering to qualified...

Ligand To Participate In Upcoming Investor Conferences

Ligand To Participate In Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: • Berenberg Conference USA in Tarrytown, New York.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AKAM, ALB, DIOD, ECOM, EZPW, FRGI, GWRS, HIBB, HLX, LGND, MTCH, OIIM, PWOD Downgrades: BWINA, BWINB, GBL, ICUI, MOC, RCM, SINA, TPRE Initiations: ARA, FBM, PUMP Read on to get TheStreet Quant Ratings' detailed report:

LGND Crosses Above Average Analyst Target

In recent trading, shares of Ligand Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $160.00, changing hands for $168.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ligand Reports First Quarter 2018 Financial Results

Ligand Reports First Quarter 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2018, and provided an operating forecast and program updates.

TheStreet Quant Rating: C (Hold)